Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human

March 15, 2016 updated by: Carlos Eduardo Pinto de Alcântara, Federal University of Minas Gerais

Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human: a Split-mouth Randomized Triple-blind Clinical Trial

The aim of this study is to evaluate the effects of hyaluronic acid (HA) on bone healing in human dental sockets.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Phase 2
  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 40 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Orthodontic need for bilateral extraction of lower first premolars

Exclusion Criteria:

  • Alcoholism, smoking, drug use and abuse of drugs; Systemic diseases: uncontrolled diabetes, blood dyscrasias, kidney or heart failure and osteoporosis; clinical or radiographic signs of pathological processes in the bone;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: hyaluronic acid
Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
Other Names:
  • Sodium hyaluronate
  • Hyaluronan
Placebo Comparator: Blood clot
Immediately after the extractions, the other side socket was naturally filled with blood clot.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of bone formation
Time Frame: 30 days after extraction and treatment application
During the postoperative interval of 30 days, the patients underwent cone beam computed tomography (CBCT). Five central transverse scan images were captured from each socket. Using the KS300 software, the gray intensity was measured in each image and the results were expressed as mean percentage of bone formation
30 days after extraction and treatment application
Fractal dimension
Time Frame: 30 days after extraction and treatment application
During the postoperative interval of 30 days, the patients underwent cone beam computed tomography (CBCT). Five central transverse scan images were captured from each socket. The pattern of the alveolar trabecular bone was also evaluated through the fractal dimension in each image.
30 days after extraction and treatment application
Dimensional Alveolar changes
Time Frame: 30 to 90 days after extraction and treatment application
To determine whether treatment could prevent loss of buccolingual thickness, was compared bone loss of 90 to 30 days between the treated and control groups.
30 to 90 days after extraction and treatment application
Percentage of bone formation
Time Frame: 90 days after extraction and treatment application
During the postoperative interval of 90 days, the patients underwent cone beam computed tomography (CBCT). Five central transverse scan images were captured from each socket. Using the KS300 software, the gray intensity was measured in each image and the results were expressed as mean percentage of bone formation
90 days after extraction and treatment application
Fractal dimension
Time Frame: 90 days after extraction and treatment application
During the postoperative interval of 90 days, the patients underwent cone beam computed tomography (CBCT). Five central transverse scan images were captured from each socket. The pattern of the alveolar trabecular bone was also evaluated through the fractal dimension in each image.
90 days after extraction and treatment application

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Anderson Ferreira, Professor, Instituto de Ciências Biológicas - Universidade Federal de Minas Gerais

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

March 1, 2016

Study Registration Dates

First Submitted

March 8, 2016

First Submitted That Met QC Criteria

March 15, 2016

First Posted (Estimate)

March 16, 2016

Study Record Updates

Last Update Posted (Estimate)

March 16, 2016

Last Update Submitted That Met QC Criteria

March 15, 2016

Last Verified

March 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alveolar Bone Loss

Clinical Trials on Placebo

3
Subscribe